PLASMIC score to aid diagnosis of aHUS: an analysis of C5 inhibitor clinical trials and the PINC AI™ healthcare database
Application of the PLASMIC Score in the aHUS diagnostic pathway may support clinical judgement and ascertain confidence in the earlier identification and subsequent treatment of patients with aHUS, thereby improving patient outcomes.
Authors
- Ching Lum
- Ioannis Tomazos (ORCID: https://orcid.org/0000-0003-0290-4583)
- Christoph Gasteyger (ORCID: https://orcid.org/0009-0002-6730-0385)
- John N. Booth (ORCID: https://orcid.org/0000-0002-6470-8951)
- Frank R. Ernst (ORCID: https://orcid.org/0000-0001-6927-9765)
- Yan Wang (ORCID: https://orcid.org/0000-0002-8150-5486)
- Miguel Giovanni Uriol Rivera (ORCID: https://orcid.org/0000-0003-1762-4226)
- Ana I Ávila
- Àngels Comas
Institutions
- Clinical Trial and Consulting (US)
- Alexion Pharmaceuticals (United States) (US)
- Hospital Universitario Doctor Peset (ES)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Spain) (ES)
- AstraZeneca (United States) (US)
- Alexion Pharma (Switzerland) (CH)
Publication Details
- Journal
- BMC Nephrology
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1186/s12882-025-04156-6
- Citations
- 1
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- AstraZeneca
- Alexion Pharmaceuticals